Barclays Global Biopharma: Your final, sortable, printable, one-stop shop ASCO 2026 planner

Research evidence excerpt

Barclays Global Biopharma: Your final, sortable, printable, one-stop shop ASCO 2026 planner

lly accepted framework or definition (legal, regulatory or otherwise) of, nor

market consensus as to what constitutes a ‘sustainable’, ‘ESG’, ‘green’, ‘climate-friendly’ or an equivalent company, investment, strategy or

consideration or what precise attributes are required to be eligible to be categorised by such terms. This means there are different ways to evaluate a

company or an investment and so different values may be placed on certain sustainability credentials as well as adverse ESG-related impacts of

companies and ESG controversies. The evolving nature of sustainable investing considerations, models and methodologies means it can be

challenging to definitively and universally classify a company or investment under a sustainable investing label and there may be areas where such

companies and investments could improve or where adverse ESG-related impacts or ESG controversies exist. The evolving nature of sustainable

finance related regulations and the development of jurisdiction-specific regulatory criteria also means that there is likely to be a degree of divergence

as to the interpretation of such terms in the market. We expect industry guidance, market practice, and regulations in this field to continue to evolve.

Any information, data, image, or other content including from a third party source contained, referred to herein or used for whatsoever purpose by

Barclays or a third party (“Information”), in relation to any actual or potential ‘ESG’, ‘sustainable' or equivalent objective, issue, factor or consideration

is not intended to be relied upon for ESG or sustainability classification, regulatory regime or industry initiative purposes (“ESG Regimes”), unless